Share information
243.30 €
-0.25 %
22/07/2026 17:35
-0.25 %
Open
High
Low
Volume
243.50 €
245.30 €
241.60 €
107,748
Latest News
08-Jul-2026
UCB presents latest data from its targeted generalized myasthenia gravis treatment portfolio at International Congress on Neuromuscular Diseases 2026
17-Jun-2026
UCB Announces Publication of Data in Brain Communications Demonstrating Positive Impact of KYGEVVI[®]▼ (doxecitine and doxribtimine) in Patients with Thymidine Kinase 2 Deficiency (TK2d)
17-Jun-2026
UCB completes acquisition of Candid Therapeutics, strengthening next generation immunology pipeline
05-Jun-2026
New EULAR 2026 data show CIMZIA[®] (certolizumab pegol) delivered consistent effect in rheumatoid arthritis, regardless of rheumatoid factor (RF) levels